Derek Lowe writes:
The axe is falling again at GlaxoSmithKline.
This time it’s the oncology group.
Last month the cardiovascular people got this same treatment, you’ll recall, and there was some disagreement about how many jobs were being affected. But it looks like the company is moving one by one through its Centers of Excellence in Drug Discovery (CEDDs) and running a most excellent scythe through them. By the time they’re through, the total number of layoffs looks like it will be substantial indeed.
More
No comments:
Post a Comment